Floatz logo

Autologous Cd19/Cd22 Chimeric Antigen Receptor T-Cells

CD19 Positive

M.D. Anderson Cancer CenterCell therapyPhase 1/2Dormant
CCC
48/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
95/ 100

Competitive context

7 Active assets in the CD19 Positive cohort.

Asset / SponsorPhaseRating
Fludarabine
Jonsson Comprehensive Cancer Center
Phase 1/2B
Cyclophosphamide
Jonsson Comprehensive Cancer Center
Phase 1/2B
CARMUSTINE
M.D. Anderson Cancer Center
Phase 1/2CCC
Epirubicin
City of Hope Medical Center
Phase 1/2CCC
Autologous Humanized Anti-Cd22 Chimeric Antigen Receptor T Cells
M.D. Anderson Cancer Center
Phase 1/2CCC

View all 18 →

Same molecule, other indications

Autologous Cd19/Cd22 Chimeric Antigen Receptor T-Cells is also rated in:

CD22 PositiveDormant
CCC
Indicative ·
48 / 100
View asset →
Progressive DiseaseDormant
CCC
Indicative ·
48 / 100
View asset →
Recurrent Non-Hodgkin LymphomaDormant
CCC
Indicative ·
48 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →